NewLink down 10% premarket

|About: NewLink Genetics Corpo... (NLNK)|By:, SA News Editor

Shares of NewLink Genetics (NLNK) are poised for a down move at the open in apparent reaction to the company's announcement of the continuation of the phase 3 IMPRESS clinical trial of algenpantucel-L for patients with surgically resected pancreatic cancer.

The interim analysis was conducted after the predetermined midpoint 222 patient events. A second interim analysis will be done after 333 patient events and, if necessary, a final analysis after 444 patient events.

The trial will involve as many as 722 patients.